Mira Pharmaceuticals' MIRA-55 shows pain relief comparable to Celebrex in rat study
MIRA•MIRA-55 matched Celebrex’s pain relief at higher doses in a 21-day study involving 72 rats. Mira plans an investigational new drug submission in the first quarter of 2027, subject to remaining preclinical and regulatory work.
1. Rat study results
Mira Pharmaceuticals said oral MIRA-55 significantly reduced mechanical and thermal pain hypersensitivity at all tested doses versus vehicle control in a 21-day study of 72 rats. At higher doses, its pain relief was comparable to Celebrex, and paw swelling declined by a similar magnitude. The company reported no observed tolerance, adverse clinical signs or deaths.
2. Planned submission
Mira plans to submit an investigational new drug application in the first quarter of 2027, subject to remaining preclinical and regulatory work.
